Title: Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
Journal: Biochemical pharmacology 20141001
Title: Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species.
Journal: The Journal of biological chemistry 20121012
Title: The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
Journal: Biochemical pharmacology 20120701
Title: Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
Journal: Molecular pharmacology 20120701
Title: A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Journal: Cancer chemotherapy and pharmacology 20120301
Title: Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.
Journal: Future oncology (London, England) 20120201
Title: Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Journal: Journal of translational medicine 20120101
Title: Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.
Journal: Journal of inorganic biochemistry 20111101
Title: Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers.
Journal: Radiation research 20111001
Title: Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Journal: Cancer chemotherapy and pharmacology 20110801
Title: Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.
Journal: International journal of radiation oncology, biology, physics 20110715
Title: Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study.
Journal: Dalton transactions (Cambridge, England : 2003) 20110614
Title: The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress.
Journal: Toxicology letters 20110305
Title: Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.
Journal: Cancer chemotherapy and pharmacology 20110201
Title: Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.
Journal: Radiation research 20101101
Title: The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Journal: Cancer chemotherapy and pharmacology 20101001
Title: Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100215
Title: A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
Journal: Investigational new drugs 20100201
Title: Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex.
Journal: Dalton transactions (Cambridge, England : 2003) 20100121
Title: Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.
Journal: Radiation research 20091201
Title: Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation.
Journal: Journal of medicinal chemistry 20090827
Title: Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
Journal: Journal of medicinal chemistry 20090528
Title: PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species.
Journal: Journal of Alzheimer's disease : JAD 20090101
Title: Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.
Journal: Bioorganic & medicinal chemistry letters 20081201
Title: A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Journal: Investigational new drugs 20080801
Title: Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Journal: Investigational new drugs 20080601
Title: A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
Journal: Investigational new drugs 20080401
Title: Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
Journal: Journal of medicinal chemistry 20080124
Title: A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Journal: Leukemia research 20080101
Title: A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Journal: Investigational new drugs 20071201
Title: Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
Journal: Journal of medicinal chemistry 20071129
Title: Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Journal: Journal of medicinal chemistry 20070726
Title: PAN-811 provides neuroprotection against glutamate toxicity by suppressing activation of JNK and p38 MAPK.
Journal: Neuroscience letters 20070705
Title: The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Journal: Biochemical pharmacology 20070515
Title: Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
Journal: Chemical research in toxicology 20070501
Title: Investigating biological activity spectrum for novel quinoline analogues.
Journal: Bioorganic & medicinal chemistry 20070201
Title: Rediscovery of the susceptibility of G6PD deficient persons to methemoglobinemia from oxidant drugs, and to hemolysis from methylene blue.
Journal: American journal of hematology 20070101
Title: Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20061201
Title: Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Journal: Leukemia research 20060701
Title: Developmental clinical trials: building one step at a time.
Journal: Leukemia research 20060701
Title: Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
Journal: The Journal of pharmacy and pharmacology 20060501
Title: Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine.
Journal: American journal of hematology 20060301
Title: A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
Journal: Molecular cancer therapeutics 20060301
Title: Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent.
Journal: CNS drug reviews 20060101
Title: Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency.
Journal: British journal of haematology 20050501
Title: PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by up-regulating Bcl-2 expression.
Journal: Neuroscience 20050101
Title: A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Journal: Cancer chemotherapy and pharmacology 20041001
Title: Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Journal: The Journal of biological chemistry 20040625
Title: Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040501
Title: Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Journal: Leukemia research 20031201
Title: Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030915
Title: Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030101
Title: The role of iron in cell cycle progression and the proliferation of neoplastic cells.
Journal: Biochimica et biophysica acta 20021002
Title: Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.
Journal: Cancer chemotherapy and pharmacology 20020901
Title: Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Journal: Current medicinal chemistry 20010201
